• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Complement activation and lung injury in Japanese patients with COVID-19: a prospective observational study

tetano

Editor, Senior Moderator
Sci Rep


. 2024 Oct 22;14(1):24895.
doi: 10.1038/s41598-024-76365-2. Complement activation and lung injury in Japanese patients with COVID-19: a prospective observational study

Kentaro Seki[SUP] 1 [/SUP], Koichiro Sueyoshi[SUP] 2 [/SUP], Yukari Miyoshi[SUP] 1 [/SUP], Yuki Nakamura[SUP] 1 [/SUP], Tadashi Ishihara[SUP] 1 [/SUP], Yutaka Kondo[SUP] 1 [/SUP], Yoko Kuroda[SUP] 1 [/SUP], Ayumi Yonekura[SUP] 3 [/SUP], Kazuhisa Iwabuchi[SUP] 3 [/SUP], Ken Okamoto[SUP] 1 [/SUP], Hiroshi Tanaka[SUP] 1 [/SUP]



Affiliations
Abstract

Background The production of inflammatory cytokines is reportedly increased in patients with coronavirus disease 2019 (COVID-19), causing the migration of neutrophils and monocytes to lung tissues. This disrupts the air-blood barrier by damaging the bronchial epithelial and vascular endothelial cells. As multiorgan dysfunction in sepsis is considered to be partly caused by complement activation, which can cause lung injury in patients with COVID-19. There are limited studies examining the link between complement activation in patients with COVID-19. This study aimed to AQinvestigate the association of complement activation with the pathophysiology of COVID-19. Twenty-seven patients with COVID-19 were enrolled in this study and classified into two groups depending on the indication for mechanical ventilation. Plasma complement factors (C3a, C5a, Ba, and sC5b-9), complement regulators (sCD59 and factor H), interleukin-6 (IL-6), and syndecan-1 levels were measured using Enzyme-linked immunosorbent assay (ELISA). Results: All complement factors and regulators, IL-6, and syndecan-1 levels were significantly elevated in patients with COVID-19 compared with those in healthy controls. C5a and sC5b-9 levels were decreased significantly in the invasive mechanical ventilation (IMV) group compared with those in the non-IMV group. Syndecan-1 levels were significantly increased in the IMV group compared with those in the non-IMV group. Conclusions: Complement activation is an exacerbating factor for lung injury in patients with COVID-19. Complement factors are nonessential predictors of mechanical ventilation; however, syndecan-1 could be a biomarker of COVID-19 severity in patients.

Keywords: COVID-19; Complement system; Invasive mechanical ventilation; Syndecan-1.

 
Back
Top Bottom